Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy
10.3971/j.issn.1000-8578.2023.22.0869
- VernacularTitle:晚期甲状腺癌治疗的曙光——靶向和免疫治疗
- Author:
Shanting LIU
1
;
Jiali QIN
;
Jie FAN
Author Information
1. Department of Head and Neck Thyroid Surgery, Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China
- Publication Type:Research Article
- Keywords:
Advanced thyroid cancer;
Targeted therapy;
Immunotherapy
- From:
Cancer Research on Prevention and Treatment
2023;50(1):6-11
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the incidence of thyroid cancer has increased significantly. Most of the cases are differentiated thyroid cancer, which is characterized by a good prognosis. However, 15% of patients still have persistent or recurrent disease after initial treatment, and those with locally advanced or metastatic cancer are not cured with established treatments and at risk of death. The treatment of advanced thyroid cancer is still controversial at home and abroad, but it tends to targeted therapy and immunotherapy. With the in-depth understanding of the molecular pathogenesis of thyroid cancer, a variety of new targeted therapies have been approved for advanced thyroid cancer. The 2021 guidelines of the Chinese Society of Clinical Oncology (CSCO) and the 2022 guidelines of the European Society of Oncology (ESMO) regard targeted therapy as a level I recommendation for the treatment of advanced thyroid cancer. This article reviews the new progress in clinical treatment of advanced thyroid carcinoma.
